Chris Lowe

Chris Lowe has a diverse work experience spanning various roles in the healthcare and biotechnology industries. In 2007, they served as the Chief Business Officer and Chief Financial Officer for Anthera Pharmaceuticals. Chris went on to become the Chairman of the Audit Committee at Asante Solutions in 2014. Later that year, they took on the role of Interim Chief Executive Officer at Hansen Medical. In 2016, they served as a Director at Inspyr Therapeutics and as a Board of Director at EpiBiome. Starting in 2014, Lowe was a Partner at FLG Partners, providing comprehensive board advisory and CFO consulting services for Silicon Valley companies. In 2017, they became the Managing Partner - Innventus Fund at Innventure, where they worked on transforming markets through partnerships with multinational corporations. In 2019, Lowe took on a dual role as the COO and CFO at Cortexyme, a company focused on developing therapeutics for degenerative disorders. Chris joined Vincerx Pharma as a Board Member in 2020, working on advancing new therapies for cancer treatment. Currently, Lowe holds the position of Chief Executive Officer at Nusano, a medical technology company committed to revolutionizing the medical radioisotopes market.

Chris Lowe has a Bachelor of Science degree in Finance from California Polytechnic State University-San Luis Obispo. Chris also holds a Master of Business Administration degree in Business from St. Mary's University. Additionally, Chris attended Bellarmine College Preparatory, although no specific degree or field of study is provided.